Treatment comparison of hydroxyurea versus ruxolitinib in essential thrombocythaemia: A matched‐cohort analysis

Abstract Hydroxyurea is the preferred first‐line cytoreductive treatment for high‐risk essential thrombocythaemia (ET), but many patients are intolerant or refractory to hydroxyurea. Ruxolitinib has been shown to improve symptoms in patients with ET. This post hoc analysis compared the clinical outc...

Full description

Bibliographic Details

Published in:	eJHaem
Main Authors:	Michael R. Grunwald, Ellen K. Ritchie, Elisa Rumi, Albert Assad, J. E. Hamer‐Maansson, Jingbo Yu, Tricia Kalafut, Evan Braunstein, Francesco Passamonti
Format:	Article
Language:	English
Published:	Wiley 2024-08-01
Subjects:	essential thrombocythaemia hydroxyurea matched‐cohort analysis ruxolitinib
Online Access:	https://doi.org/10.1002/jha2.954